OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
Yan‐Jun Xiang, Kang Wang, Hongming Yu, et al.
Hepatology Research (2022) Vol. 52, Iss. 8, pp. 721-729
Closed Access | Times Cited: 33
Yan‐Jun Xiang, Kang Wang, Hongming Yu, et al.
Hepatology Research (2022) Vol. 52, Iss. 8, pp. 721-729
Closed Access | Times Cited: 33
Showing 1-25 of 33 citing articles:
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
Xu Yang, Bowen Chen, Yanyu Wang, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 709-719
Open Access | Times Cited: 42
Xu Yang, Bowen Chen, Yanyu Wang, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 709-719
Open Access | Times Cited: 42
Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies
Lilong Zhang, Jiarui Feng, Tianrui Kuang, et al.
International Immunopharmacology (2023) Vol. 118, pp. 110019-110019
Open Access | Times Cited: 35
Lilong Zhang, Jiarui Feng, Tianrui Kuang, et al.
International Immunopharmacology (2023) Vol. 118, pp. 110019-110019
Open Access | Times Cited: 35
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
Yujing Xin, Xinyuan Zhang, Ning Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 753-764
Closed Access | Times Cited: 33
Yujing Xin, Xinyuan Zhang, Ning Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 753-764
Closed Access | Times Cited: 33
Efficacy and safety of TACE combined with lenvatinib and PD ‐1 inhibitors for unresectable recurrent HCC : A multicenter, retrospective study
Weijun Wang, Zong‐Han Liu, Kang Wang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11513-11524
Open Access | Times Cited: 18
Weijun Wang, Zong‐Han Liu, Kang Wang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11513-11524
Open Access | Times Cited: 18
Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma
Sheng Ye, Qing Wang, Haifeng Liu, et al.
British Journal of Radiology (2024) Vol. 97, Iss. 1155, pp. 668-679
Closed Access | Times Cited: 6
Sheng Ye, Qing Wang, Haifeng Liu, et al.
British Journal of Radiology (2024) Vol. 97, Iss. 1155, pp. 668-679
Closed Access | Times Cited: 6
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis
Lei Wang, Lin Li, Wei Zhou
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108634-108634
Closed Access | Times Cited: 6
Lei Wang, Lin Li, Wei Zhou
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108634-108634
Closed Access | Times Cited: 6
Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate‐stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
Yitao Zheng, Yan‐Jun Xiang, Hongqi Shi, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1079-1093
Open Access | Times Cited: 6
Yitao Zheng, Yan‐Jun Xiang, Hongqi Shi, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1079-1093
Open Access | Times Cited: 6
Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study
Zeyu Yu, Bin Leng, Ran You, et al.
Investigational New Drugs (2025)
Open Access
Zeyu Yu, Bin Leng, Ran You, et al.
Investigational New Drugs (2025)
Open Access
Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
Hongyu Pan, Minghao Ruan, Riming Jin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Hongyu Pan, Minghao Ruan, Riming Jin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
Laihui Luo, Yongzhu He, Guoqing Zhu, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 1353-1368
Open Access | Times Cited: 21
Laihui Luo, Yongzhu He, Guoqing Zhu, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 1353-1368
Open Access | Times Cited: 21
Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics
Jiayi Wu, Junyi Wu, Shuqun Li, et al.
BioScience Trends (2024) Vol. 18, Iss. 1, pp. 42-48
Open Access | Times Cited: 4
Jiayi Wu, Junyi Wu, Shuqun Li, et al.
BioScience Trends (2024) Vol. 18, Iss. 1, pp. 42-48
Open Access | Times Cited: 4
New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma
Hanyuan Liu, Chunmei Wang, Ruiqiang Wang, et al.
Chinese Journal of Cancer Research (2024) Vol. 36, Iss. 2, pp. 167-194
Open Access | Times Cited: 4
Hanyuan Liu, Chunmei Wang, Ruiqiang Wang, et al.
Chinese Journal of Cancer Research (2024) Vol. 36, Iss. 2, pp. 167-194
Open Access | Times Cited: 4
Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
Peng Guo, Xingtao Pi, Feng Gao, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 18
Peng Guo, Xingtao Pi, Feng Gao, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 18
Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Tao Meng, Jing Han, Juanyi Shi, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1069-1083
Open Access | Times Cited: 10
Tao Meng, Jing Han, Juanyi Shi, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1069-1083
Open Access | Times Cited: 10
Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
Haohao Lu, Bin Liang, Xiangwen Xia, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Haohao Lu, Bin Liang, Xiangwen Xia, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors – a systematic review and meta-analysis
Zaiba Shafik Dawood, Zachary J. Brown, Laura Alaimo, et al.
HPB (2024) Vol. 26, Iss. 5, pp. 618-629
Closed Access | Times Cited: 3
Zaiba Shafik Dawood, Zachary J. Brown, Laura Alaimo, et al.
HPB (2024) Vol. 26, Iss. 5, pp. 618-629
Closed Access | Times Cited: 3
Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
Liwei Sun, Xuelong Xu, Fanguang Meng, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 15
Liwei Sun, Xuelong Xu, Fanguang Meng, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 15
Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Junning Liu, Wei Song, Linfeng Yang, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 15, pp. 14451-14461
Closed Access | Times Cited: 7
Junning Liu, Wei Song, Linfeng Yang, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 15, pp. 14451-14461
Closed Access | Times Cited: 7
Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma
Bo Sun, Lei Chen, Lei Yu, et al.
British Journal of Radiology (2024) Vol. 97, Iss. 1159, pp. 1320-1327
Open Access | Times Cited: 2
Bo Sun, Lei Chen, Lei Yu, et al.
British Journal of Radiology (2024) Vol. 97, Iss. 1159, pp. 1320-1327
Open Access | Times Cited: 2
An overview: Management of patients with advanced hepatocellular carcinoma
Jincheng Wang, Rui Wu, Jin-Yu Sun, et al.
BioScience Trends (2022) Vol. 16, Iss. 6, pp. 405-425
Open Access | Times Cited: 11
Jincheng Wang, Rui Wu, Jin-Yu Sun, et al.
BioScience Trends (2022) Vol. 16, Iss. 6, pp. 405-425
Open Access | Times Cited: 11
Lenvatinib plus sintilimab with or without transarterial chemoembolization for intermediate or advanced stage hepatocellular carcinoma: a propensity score-matching cohort study.
Mengran Lang, Leijuan Gan, Shaohua Ren, et al.
PubMed (2023) Vol. 13, Iss. 6, pp. 2540-2553
Closed Access | Times Cited: 6
Mengran Lang, Leijuan Gan, Shaohua Ren, et al.
PubMed (2023) Vol. 13, Iss. 6, pp. 2540-2553
Closed Access | Times Cited: 6
Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
Teng Long, Zhoutian Yang, Huilan Zeng, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1849-1859
Open Access | Times Cited: 4
Teng Long, Zhoutian Yang, Huilan Zeng, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1849-1859
Open Access | Times Cited: 4
The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study
Xi‐Shu Wang, Ximin Sun, Yongrong Lei, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Xi‐Shu Wang, Ximin Sun, Yongrong Lei, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review
Jingxin Yan, Manjun Deng, Shunyu Kong, et al.
iLiver (2022) Vol. 1, Iss. 4, pp. 225-234
Closed Access | Times Cited: 7
Jingxin Yan, Manjun Deng, Shunyu Kong, et al.
iLiver (2022) Vol. 1, Iss. 4, pp. 225-234
Closed Access | Times Cited: 7
Cholesterol and C-reactive protein prognostic score predicted prognosis of immune checkpoint inhibitors based interventional therapies for intermediate-to-advanced hepatocellular carcinoma patients
Huilan Zeng, Deyao Zhang, Zhenyun Yang, et al.
International Immunopharmacology (2023) Vol. 115, pp. 109651-109651
Open Access | Times Cited: 3
Huilan Zeng, Deyao Zhang, Zhenyun Yang, et al.
International Immunopharmacology (2023) Vol. 115, pp. 109651-109651
Open Access | Times Cited: 3
